Modelling of the biopharmaceutical drug development pathway and portfolio management

Computers and Chemical Engineering

Volumn 29, Issue 6 SPEC. ISS., 2005, Pages 1357-1368

  Rajapakse, Anuradha ^a   Titchener Hooker, Nigel John ^a   Farid, Suzanne S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biopharmaceutical drug development; Computer aided simulation; Decision support tool; Portfolio management; Risk

Indexed keywords

CLINICAL LABORATORIES; DECISION MAKING; DRUG PRODUCTS PLANTS; MATHEMATICAL MODELS; OUTSOURCING; PROCESS CONTROL;

BIOPHARMACEUTICAL DRUG DEVELOPMENT; CLINICAL TRIALS; COMPUTER TOOLS; PORTFOLIO MANAGEMENT;

DRUG PRODUCTS;

BIOTECHNOLOGY;

EID: 18244397919     PISSN: 00981354     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compchemeng.2005.02.010     Document Type: Conference Paper

References (22)

1. D. Byrom Role and timing of process development for biopharmaceutical manufacture Pharmaceutical Technology Europe 12 3 2000 52 56
2. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: New estimates of drug development costs Journal of Health Economics 22 2003 151 185
3. Farid, S. (2001). A decision-support tool for simulating the process and business perspectives of biopharmaceutical manufacture, University College London, Ph.D. Thesis.
4. S. Farid, J.L. Novais, J. Washbrook, and N.J. Titchener-Hooker A tool for modelling strategic decisions in cell culture manufacturing Biotechnology Progress 16 2000 829 836
5. S. Farid, J. Washbrook, and N.J. Titchener-Hooker Decision-support tool for risk analysis in biopharmaceutical manufacture D. Dochain M. Perrier Eighth International Conference on Computer Applications in Biotechnology (CAB8): Modelling and Control of Biotechnological Processes IFAC, EF 2001 167 171
6. F. Foo, S. Karri, E. Davies, N. Titchener-Hooker, and P. Dunnill Biopharmaceutical process development. Part I. Information from the first product generation Biopharm Europe 2001 58 64
7. G. Gatica, L.G. Papageorgiou, and N. Shah Capacity planning under uncertainty for the pharmaceutical industry Transactions of IChemE 81 (A) 2003 665 667
8. Ginsberg, P.L., Bhatia, S., & McMinn, R.L. (2002). The Road Ahead for Biologics Manufacturing, U.S. Bancorp Piper Jaffray Equity Research, NY, http://www.piperjaffray.com (accessed 2003).
9. V. Jain, and I.E. Grossmann Resource-constrained scheduling of tests in new product development Industrial and Engineering Chemistry Research 38 1999 3013 3026
10. S. Karri, E. Davies, N.J. Titchener-Hooker, and J. Washbrook Biopharmaceutical process development. Part III. A framework to assist decision making Biopharm Europe 2001 76 82
11. Keelin, T., Shew, B. (2003). Third Generation Portfolio Management. Strategic Decisions Group Publication.
12. E.S. Langer Manufacturing capacity put on simmer Bioprocess International 2004 22 28
13. A.A. Levis, and L.G. Papageorgiou A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry Computers and Chemical Engineering 28 2004 707 725
14. A.C. Lim, J. Washbrook, N.J. Titchener-Hooker, and S. Farid A decisional-support tool to model the impact of regulatory compliance activities in the biomanufacturing industry Computers and Chemical Engineering 28 5 2004 727 735
15. T.A. Luehrman Financial engineering at Merck Harvard Business Review 1994 94 97
16. M.A. Mustafa, J. Washbrook, A.C. Lim, Y. Zhou, N.J. Titchener-Hooker, P. Morton, S. Berezenko, and S.S. Farid A software tool to assist business-process decision-making in the biopharmaceutical industry Biotechnology Progress 20 4 2004 1096 1102
17. I. Nicholson, and P. Latham When make or buy means make or break Bio/Technology 12 1994 473 477
18. J.M. Reichert Monoclonal antibodies in the clinic Nature Biotechnology 2001 19
19. M.J. Rogers, A. Gupta, and C.D. Maranas Real options based analysis of optimal pharmaceutical research and development portfolios Industrial and Engineering Chemistry Research 41 2002 6607 6620
20. M. Soegaard Maximising return on investment with R&D portfolio management European Biopharmaceutical Review 2003 12 15
21. J.S. Stonebraker How Bayer makes decisions to develop new drugs Interfaces 32 6 2002 77 90
22. D. Subramanian, J.F. Pekny, and G.V. Reklaitis A simulation-optimisation framework for addressing combinatorial and stochastic aspects of an R&D pipeline management problem Computers and Chemical Engineering 24 2000 1005 1011